Paul E A Glaser
Overview
Explore the profile of Paul E A Glaser including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
872
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xu K, Mintz C, Borodovsky J, Glaser P, Bierut L, Grucza R
Prim Care Companion CNS Disord
. 2021 Aug;
23(4).
PMID: 34352941
No abstract available.
2.
Herting M, Uban K, Gonzalez M, Baker F, Kan E, Thompson W, et al.
Front Endocrinol (Lausanne)
. 2021 Mar;
11:549928.
PMID: 33679599
Aim: To examine individual variability between perceived physical features and hormones of pubertal maturation in 9-10-year-old children as a function of sociodemographic characteristics. Methods: Cross-sectional metrics of puberty were utilized...
3.
Mintz C, Presnall N, Sahrmann J, Borodovsky J, Glaser P, Bierut L, et al.
Drug Alcohol Depend
. 2020 Oct;
216:108312.
PMID: 33007704
No abstract available.
4.
Mintz C, Presnall N, Sahrmann J, Borodovsky J, Glaser P, Bierut L, et al.
Drug Alcohol Depend
. 2020 Jun;
213:108130.
PMID: 32593972
Background And Aims: Adolescents with opioid use disorder (OUD) are an understudied and vulnerable population. We examined the association between age and six-month treatment retention, and whether any such association...
5.
Miller E, Quintero J, Pomerleau F, Huettl P, Gerhardt G, Glaser P
Neurochem Res
. 2018 Feb;
44(1):89-101.
PMID: 29397534
Glutamate dysfunction has been implicated in a number of substance of abuse studies, including cocaine and methamphetamine. Moreover, in attention-deficit/hyperactivity disorder (ADHD), it has been discovered that when the initiation...
6.
Lile J, Stoops W, Rush C, Negus S, Glaser P, Hatton K, et al.
Drug Alcohol Depend
. 2016 Jun;
165:111-9.
PMID: 27269368
Background: A medication for treating cocaine use disorder has yet to be approved. Laboratory-based evaluation of candidate medications in animals and humans is a valuable means to demonstrate safety, tolerability...
7.
Marks K, Lile J, Stoops W, Glaser P, Hays L, Rush C
J Clin Psychopharmacol
. 2016 Apr;
36(3):213-21.
PMID: 27043121
Opioid antagonists (eg, naltrexone) and positive modulators of γ-aminobutyric acid type A receptors (eg, alprazolam) each modestly attenuate the abuse-related effects of stimulants. A previous study demonstrated that acute pretreatment...
8.
Miller E, Quintero J, Pomerleau F, Huettl P, Gerhardt G, Glaser P
J Neurosci Methods
. 2015 Jan;
252:75-9.
PMID: 25614383
Background: The aberrant regulation of glutamate has been implicated in numerous psychiatric disorders including drug addiction and attention-deficit/hyperactivity disorder. To understand glutamate signaling and its role in facilitating disease, tools...
9.
Pike E, Stoops W, Hays L, Glaser P, Rush C
J Clin Psychopharmacol
. 2014 Aug;
34(6):675-81.
PMID: 25154010
Agonist replacement may be a viable treatment approach for managing stimulant use disorders. This study sought to determine the effects of D-amphetamine maintenance on methamphetamine self-administration in stimulant using human...
10.
Leuchter A, McGough J, Korb A, Hunter A, Glaser P, Deldar A, et al.
J Psychiatr Res
. 2014 Apr;
54:11-8.
PMID: 24726639
Atomoxetine is a non-stimulant medication with sustained benefit throughout the day, and is a useful pharmacologic treatment option for young adults with Attention-Deficit/Hyperactivity Disorder (ADHD). It is difficult to determine,...